Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DC Vaccine for Metastatic Melanoma
NCT00334776Phase 2Completed
- Sponsor
- University of Southern California
- Start
- Oct 2003
- Primary completion
- Jun 2005
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of mart-1 + gp100 + tyrosinase + dendritic cell vaccine in melanoma, sponsored by University of Southern California. Started Oct 2003; status: completed.
02
Drugs
mart-1 + gp100 + tyrosinase + dendritic cell vaccine
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00334776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00334776.